ACTINIUM PHARMACEUTICALS INC

Actinium Pharmaceuticals (ATNM) surges 15.94% amid investor optimism, beating peers with a promising antibody‑radiation pipeline and solid 200‑day MA support.

Actinium Pharmaceuticals (ATNM) slips 1.4% after a near‑18% rally—still trading above its 200‑day average and within a favorable range for early‑stage biopharma investors.

Actinium (ATNM) hits a 6.06% rise, touts first‑in‑human Phase I success for HER3‑targeted ATNM‑400, positioning itself as a pan‑tumor radiotherapy leader.

Actinium (ATNM) jumps 16.81% in a single day, defying micro‑cap norms. Discover the catalyst, liquidity risks, and regulatory hurdles behind this high‑risk, high‑reward surge.